Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.